Clinical Trial

ONO-4538 Phase II Rollover Study (ONO-4538-98)

Name: ONO-4538 Phase II Rollover Study (ONO-4538-98) — clinical trial record (NCT04566380)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Recruiting Phase 2

View on ClinicalTrials.gov →

Summary

This study is intended to confirm the long-term safety of ONO-4538 in pan-tumor participants being treated with ONO-4538 monotherapy or in Combination with Other Therapies in clinical trials.

Protocol Amendment History 11 amendments

This ClinicalTrials.gov record has been amended 11 times since 2020-09-22; most recent amendment 2025-06-01.

Trial Details

NCT Number	NCT04566380
Lead Sponsor	Ono Pharmaceutical Co., Ltd.
Conditions	Pan-tumor
Enrollment	59 participants
Start Date	2020-09-10
Primary Completion	2026-12-31 (estimated)
Study Completion	2026-12-31 (estimated)
Updated on ClinicalTrials.gov	2025-06-03